<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989596</url>
  </required_header>
  <id_info>
    <org_study_id>SINDIR1</org_study_id>
    <nct_id>NCT03989596</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas</brief_title>
  <acronym>SINDIR</acronym>
  <official_title>Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a screening, which consists of biopsy, physical examination, initial diffusion-weighted
      magnetic resonance imaging (DWI-MRI) or body computed tomography (CT) scan, blood tests and
      case analysis on Multidisciplinary Team (MDT) meeting, a patient will receive the
      hypofractionated radiotherapy 10x 3.25 Gy with deep hyperthermia (twice a week) within two
      weeks. The response analysis in CT or DWI-MRI and toxicity assessment will be performed after
      6 weeks. On the second MDT meeting, a final decision about resectability of the tumor will be
      made. In case of resectability, a patient will be referred to surgery. In case of
      unresectability the patient will receive a boost which consists of 4x 4 Gy with deep
      hyperthermia (twice a week).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a lack of standard treatment of unresectable and marginally resectable sarcomas.
      Results of commonly used approaches are unsatisfactory, especially in patients who are not
      candidates for neoadjuvant chemotherapy due to poor performance status, comorbidities,
      radioresistant pathology or disease progression on the commonly used chemotherapy regimens.
      The addition of deep hyperthermia to irradiation and in the prolonged gap between the end of
      hypofractionated 10x 3.25 Gy radiotherapy and surgery may allow obtaining the long-term local
      control with the maintenance of a good treatment tolerance.

      Hypofractionation represents a variation of radiotherapy fractionation in which the total
      dose is divided into fewer fractions with an increased fraction dose. Such treatment may lead
      to additional biological effects when compared to conventionally fractionated radiotherapy
      (eg. vascular damage, increased immunogenicity, and antigenicity). The main advantages of
      hypofractionation are those related to the decreased overall treatment time which is more
      convenient for both patients and physicians, increased compliance and makes the treatment
      more cost-effective. Intriguing, such an approach may provide an additional benefit when
      treating non-radiosensitive tumors with a low alpha/beta ratio (eg. sarcomas).

      Hyperthermia is a method of increasing the temperature in the tumor to damage cancer cells
      with minimum injury to the normal cells. It should be combined with another treatment
      modality (radio- or chemotherapy) rather than used alone. Its efficacy was proven in clinical
      trials. The treatment tolerance is usually very good.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade 3 or higher early toxicity of planned schedule of therapy according to RTOG/EORTC scale</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year local control rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year cancer-specific survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of late treatment toxicity, at 6 and 12 months, according to RTOG/EORTC scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sarcoma</condition>
  <condition>Alveolar Soft Part Sarcoma</condition>
  <condition>Clear Cell Sarcoma</condition>
  <condition>Malignant Peripheral Nerve Sheath Tumors</condition>
  <condition>Myxoid Liposarcoma</condition>
  <condition>Liposarcoma, Dedifferentiated</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Undifferentiated Pleomorphic Sarcoma</condition>
  <condition>Fibrosarcoma</condition>
  <condition>Pleomorphic Rhabdomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy with hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks.</description>
    <arm_group_label>Radiotherapy with hyperthermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperthermia</intervention_name>
    <description>Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.</description>
    <arm_group_label>Radiotherapy with hyperthermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent; age ≥18 years old

          -  Eastern Cooperative Oncology Group performance status 0 - 2

          -  Histologic diagnosis of soft tissue sarcoma

          -  Age &gt; 70 years, or ten-year survival &lt;40% as predicted in Charlson Comorbidity Index,
             or non-operability from other reasons, or chemoresistant tumor (histology or
             progression after neoadjuvant chemotherapy)

        Exclusion Criteria:

          -  Radiation-induced sarcoma or previous radiation to the affected volume

          -  Histologic diagnosis of rhabdomyosarcoma (except pleomorphic subtype), osteogenic
             sarcoma, Ewing's sarcoma/PNET, aggressive fibromatosis

          -  Contraindications to radiotherapy or hyperthermia

          -  Unresectable metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mateusz J Spałek, MD</last_name>
    <phone>+48225462455</phone>
    <email>mateusz.spalek@coi.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aneta Borkowska, MD</last_name>
    <phone>+48225462455</phone>
    <email>aneta.borkowska@coi.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Institute - Oncology Center</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovian</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Rutkowski, MD PhD Professor</last_name>
      <phone>+48226439375</phone>
      <email>piotr.rutkowski@coi.pl</email>
    </contact>
    <investigator>
      <last_name>Mateusz J Spałek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aneta Borkowska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tadeusz Morysiński, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konrad Pawlewicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorota Kiprian, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaudia Lewcio-Szczęsna, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daria Niebyłowska, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Telejko, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Kawecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Rutkowski, MD PhD Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Koseła-Paterczyk H, Szacht M, Morysiński T, Ługowska I, Dziewirski W, Falkowski S, Zdzienicki M, Pieńkowski A, Szamotulska K, Switaj T, Rutkowski P. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014 Dec;40(12):1641-7. doi: 10.1016/j.ejso.2014.05.016. Epub 2014 Sep 20.</citation>
    <PMID>25282099</PMID>
  </reference>
  <reference>
    <citation>Lindner LH, Issels RD. Hyperthermia in soft tissue sarcoma. Curr Treat Options Oncol. 2011 Mar;12(1):12-20. doi: 10.1007/s11864-011-0144-6. Review.</citation>
    <PMID>21360087</PMID>
  </reference>
  <reference>
    <citation>Pennacchioli E, Fiore M, Gronchi A. Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. Expert Rev Anticancer Ther. 2009 Feb;9(2):199-210. doi: 10.1586/14737140.9.2.199. Review.</citation>
    <PMID>19192958</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose Hypofractionation</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Hyperthermia</keyword>
  <keyword>Dose Fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

